| CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo J Dietrich, R Han, Y Yang, M Mayer-Pröschel, M Noble Journal of biology 5, 1-23, 2006 | 612 | 2006 |
| Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system R Han, YM Yang, J Dietrich, A Luebke, M Mayer-Pröschel, M Noble Journal of biology 7, 1-22, 2008 | 389 | 2008 |
| Tegavivint and the β-catenin/ALDH axis in chemotherapy-resistant and metastatic osteosarcoma M Nomura, N Rainusso, YC Lee, B Dawson, C Coarfa, R Han, JL Larson, ... JNCI: Journal of the National Cancer Institute 111 (11), 1216-1227, 2019 | 82 | 2019 |
| MEK1/2 inhibition suppresses tamoxifen toxicity on CNS glial progenitor cells HY Chen, YM Yang, R Han, M Noble Journal of Neuroscience 33 (38), 15069-15074, 2013 | 24 | 2013 |
| Redox biology in normal cells and cancer: restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment M Noble, M Mayer-Pröschel, Z Li, T Dong, W Cui, C Pröschel, ... Free Radical Biology and Medicine 79, 300-323, 2015 | 20 | 2015 |
| In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: a report from the Pediatric … RT Kurmasheva, SW Erickson, R Han, BA Teicher, MA Smith, M Roth, ... Pediatric blood & cancer 68 (11), e29304, 2021 | 19 | 2021 |
| Targeting oncogenic Wnt/β-catenin signaling in adrenocortical carcinoma disrupts ECM expression and impairs tumor growth MK Penny, AM Lerario, KJ Basham, S Chukkapalli, DR Mohan, ... Cancers 15 (14), 3559, 2023 | 13 | 2023 |
| Transducin b-like protein 1 controls multiple oncogenic networks in diffuse large B-cell lymphoma Y Youssef, V Karkhanis, WK Chan, F Jeney, A Canella, X Zhang, S Sloan, ... haematologica 106 (11), 2927, 2021 | 13 | 2021 |
| Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors DA Braggio, F Costas C. de Faria, D Koller, F Jin, A Zewdu, G Lopez, ... Plos one 17 (10), e0276047, 2022 | 11 | 2022 |
| ONM-501: A polyvalent STING agonist for oncology immunotherapy S Li, J Wang, J Wilhelm, Q Su, G Bharadwaj, J Miller, W Li, K Torres, ... Cancer Research 82 (12 Supplement), 4234, 2022 | 5 | 2022 |
| Methods for treatment of fibrotic diseases R Han, J Northrup, S Kasibhatla, S Horrigan, J Larson US Patent 11,298,346, 2022 | 4 | 2022 |
| Immu-19. LSD1 modulates nk cell immunotherapy through an onco-immunogenic gene signature in dipg C Bailey, M Romero, R Han, J Larson, O Becher, D Lee, M Monje, ... Neuro-Oncology 20 (Suppl 2), i102, 2018 | 3 | 2018 |
| Abstract LB245: ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile Z Chen, G Huang, K Torres, F Stavros, A Ahmed, J Miller, T Zhao, J Gao, ... Cancer Research 83 (8_Supplement), LB245-LB245, 2023 | 2 | 2023 |
| Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system H Ruolan, D Joerg, L Anne, MP Margot, N Mark | 2 | 2008 |
| Improved tolerability and tumor specific delivery of a therapeutic bispecific T cell engager using a pH-sensitive nanoparticle platform Q Su, S Gutowski, G Bharadwaj, A Burcham, B Allu, I Kalashnikova, ... Cancer Research 83 (7_Supplement), 815-815, 2023 | 1 | 2023 |
| 1155 ONM-501, a polyvalent STING agonist, exhibits anti-tumor efficacy with increased tumor T-cell infiltration in mice and is well tolerated in rats and non-human primates Z Chen, J Miller, W Li, K Torres, Q Su, G Huang, YSO Albaroodi, R Morsch, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| 1329 ultra-pH sensitive nanoparticles increase therapeutic index of IL-2-Fc Q Feng, G Huang, R Pantoja, Z Sun, W Li, K Torres, J Wilhelm, Z Chen, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| In vivo evaluation of the LSD1 inhibitor SP-2577 against Ewing sarcoma and rhabdomyosarcoma preclinincal models: A report from the Pediatric Preclinical … PJ Houghton, SW Erickson, B Teicher, MA Smith, R Han, R Kurmasheva Cancer Research 79 (13_Supplement), 3848-3848, 2019 | 1 | 2019 |
| Tegavivint suppresses progression and metastasis of osteosarcoma via blockade of Wnt signaling/ALDH1 axis: Preclinical study of a novel Wnt/β-catenin pathway inhibitor M Nomura, NC Rainusso, R Han, J Larson, RL Shuck, L Kurenbekova, ... Cancer Research 78 (13_Supplement), 3186-3186, 2018 | 1 | 2018 |
| PROTONATED pH RESPONSIVE POLYMER ENCAPSULATION OF BISPECIFIC ANTIBODIES AND CYTOKINES T Zhao, S Gutowski, I Kalashnikova, SU Qingtai, J Miller, G Bharadwaj, ... US Patent App. 18/502,783, 2024 | | 2024 |
Mark NobleUniversity of Rochester在 urmc.rochester.edu 的电子邮件经过验证
